Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Agilent launches microRNA assays:

This article was originally published in Clinica

Executive Summary

Agilent has launched three microRNA microarray designs worldwide. The assays are updated versions of Agilent's first human microarray system, which was launched in April 2007, the Santa Clara, California-based firm said. The three tests (Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0) measure the expression of microRNAs, short single-stranded RNA molecules which can regulate the production of proteins in the cell. They have been found to correlate with various disease states and could be used as biomarkers. Agilent said that pharmaceutical companies and academia were using the assays mainly to study cancer. Rosetta Genomics is also developing microRNA-based diagnostic tests for different forms of cancer, which it hopes to launch this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel